Urologic oncology · 2026
Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bansal Rahul K, Cassim Raees, Mallick Ranjeeta, Pouliot Frederic, Mannas Miles P, Finelli Antonio, Tanguay Simon, Lavallée Luke T, Nayak Jasmir G, Rendon Ricardo A, Bhindi Bimal, Wood Lori A, Lattouf Jean-Baptiste, Dean Lucas, Basappa Naveen, Bjarnason Georg, Lalani Aly-Khan A, Breau Rodney H
Аннотация
BACKGROUND AND OBJECTIVE: Reported outcomes of partial nephrectomy (PN) for cT2 renal cell carcinoma (RCC) have been variable. We aimed to examine outcomes of PN, compared to radical nephrectomy (RN) for cT2 RCC.
METHODS: Patients captured in the Canadian Kidney Cancer information system who underwent surgery for cT2 RCC between 2011 and 2023 were included. Clear cell, papillary, and chromophobe histologies were included. Multifocal tumors, and hereditary RCC syndromes were excluded. Groups were matched up to 1:4 based on tumor size, histology, grade and necrosis.
KEY FINDINGS AND LIMITATIONS: Of 1778 cT2 patients, 60 PN patients were matched to 224 RN patients. Positive surgical margins were 8.6% for PN vs. 2.8% for RN (P = 0.06). Postoperative complications were 18.3% for PN vs. 9.8% for RN (P = 0.07). Pathological upstaging to T3 was similar (21.7% PN vs. 22.3% RN, P = 0.73). There were no statistically significant recurrence or survival outcomes, however there were non-significant trends in local recurrence (HR 2.07, 95%CI 0.86-5.0), cancer specific survival (HR 0.65, 95%CI 0.19-2.16), overall survival (HR 0.66, 95%CI 0.28-1.57) for PN vs. RN. PN better preserved eGFR (-15.5 [IQR 27.7] vs. -24.4 [IQR 21.5], P = 0.026).
CONCLUSIONS AND CLINICAL IMPLICATIONS: In a cohort of patients with non-metastatic cT2 RCC, PN has better preservation of renal function and may have a higher rate of perioperative complications and local recurrence. Acknowledging the presence of residual confounding, PN for T2 RCC is safe and provides acceptable oncological outcomes in well-selected patients.
METHODS: Patients captured in the Canadian Kidney Cancer information system who underwent surgery for cT2 RCC between 2011 and 2023 were included. Clear cell, papillary, and chromophobe histologies were included. Multifocal tumors, and hereditary RCC syndromes were excluded. Groups were matched up to 1:4 based on tumor size, histology, grade and necrosis.
KEY FINDINGS AND LIMITATIONS: Of 1778 cT2 patients, 60 PN patients were matched to 224 RN patients. Positive surgical margins were 8.6% for PN vs. 2.8% for RN (P = 0.06). Postoperative complications were 18.3% for PN vs. 9.8% for RN (P = 0.07). Pathological upstaging to T3 was similar (21.7% PN vs. 22.3% RN, P = 0.73). There were no statistically significant recurrence or survival outcomes, however there were non-significant trends in local recurrence (HR 2.07, 95%CI 0.86-5.0), cancer specific survival (HR 0.65, 95%CI 0.19-2.16), overall survival (HR 0.66, 95%CI 0.28-1.57) for PN vs. RN. PN better preserved eGFR (-15.5 [IQR 27.7] vs. -24.4 [IQR 21.5], P = 0.026).
CONCLUSIONS AND CLINICAL IMPLICATIONS: In a cohort of patients with non-metastatic cT2 RCC, PN has better preservation of renal function and may have a higher rate of perioperative complications and local recurrence. Acknowledging the presence of residual confounding, PN for T2 RCC is safe and provides acceptable oncological outcomes in well-selected patients.